Arcus Biosciences Inc (RCUS) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Arcus Biosciences Inc (US:RCUS), trading at 28.25. In 2025, Arcus Biosciences Inc generated $247.00 Million in revenue and -$484.00 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Arcus Biosciences Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 28.25
- Recent Revenue (2025): $247.00 Million
- Free Cash Flow (2025): -$484.00 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.